Testing RIG-101 in healthy adults and adults with asthma
Part of Lungs & breathing clinical trials.
This trial tests an experimental medicine called RIG-101 in healthy adults and adults with asthma. The goal is to see if it can safely prevent or reduce asthma worsening after exposure to a common cold virus (rhinovirus).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- If you have asthma, it must be confirmed by a doctor and well-controlled with your current medication (like a rescue inhaler or daily inhaled steroid).
- You have never had a severe asthma attack that put you in the intensive care unit.
- You do not use any biologic treatments for asthma (like Xolair, Nucala, or Fasenra).
- You haven't smoked or used nicotine products (including e-cigarettes) in the past 6 months.
- You have not had a cold, flu, or sinus infection in the past 6 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if an investigational nasal spray (ETH47) can reduce asthma symptoms triggered by a common cold virus (rhinovirus). You will be exposed to the virus in a safe setting to see if the spray helps control your asthma.
This trial studies new technologies to help doctors diagnose asthma and better understand airway inflammation. It may help you (or healthy volunteers, if eligible) by allowing your breathing tests and inflammation markers to be measured with newer diagnostic tools.
This trial tests an inhaled medication for people with bronchiectasis, a lung condition causing chronic cough and mucus. It first checks safety in healthy volunteers, then studies how the drug works in people with bronchiectasis.
This study tests whether giving a common cold virus (rhinovirus) to people with bronchiectasis and healthy volunteers can trigger a lung flare-up. It aims to understand how the immune system responds and what causes exacerbations, which could lead to better treatments.
This early-phase study tests an inhaled medication (CHF10136) to see if it's safe and how the body handles it. It includes both healthy adults and people with asthma, and participants will be monitored closely throughout.
This Phase 2 study tests a “viral” treatment meant to reprogram the lining of your nose to reduce allergy-like immune responses. It is testing whether this approach is safe and can help people with cat allergy (with or without asthma) or compare against healthy people.
Hear when a new Healthy Adult Participants trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.